{"id":"https://openalex.org/W1975721982","doi":"https://doi.org/10.1177/00912700222011148","title":"Pharmacokinetic and Pharmacodynamic Assessments of HMG\u2010CoA Reductase Inhibitors When Coadministered with Everolimus","display_name":"Pharmacokinetic and Pharmacodynamic Assessments of HMG\u2010CoA Reductase Inhibitors When Coadministered with Everolimus","publication_year":2002,"publication_date":"2002-02-01","ids":{"openalex":"https://openalex.org/W1975721982","doi":"https://doi.org/10.1177/00912700222011148","mag":"1975721982","pmid":"https://pubmed.ncbi.nlm.nih.gov/11831546"},"language":"en","primary_location":{"id":"doi:10.1177/00912700222011148","doi":"https://doi.org/10.1177/00912700222011148","is_oa":false,"landing_page_url":"https://doi.org/10.1177/00912700222011148","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113699560","display_name":"John M. Kovarik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"John M. Kovarik","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010774833","display_name":"Stefan Hartmann","orcid":"https://orcid.org/0000-0003-2727-1858","observed_orcids":["https://orcid.org/0000-0003-2727-1858"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Stefan Hartmann","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060982119","display_name":"Martine Hubert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martine Hubert","raw_affiliation_strings":["Rueil-Malmaison, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rueil-Malmaison, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062111345","display_name":"Stephane Berthier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Stephane Berthier","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061689630","display_name":"Werner Schneider","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Werner Schneider","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058578660","display_name":"Bernd Rosenkranz","orcid":"https://orcid.org/0000-0002-9867-8826","observed_orcids":["https://orcid.org/0000-0002-9867-8826"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bernd Rosenkranz","raw_affiliation_strings":["Parexel, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parexel, Berlin, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109170528","display_name":"Christiane M Rordorf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Christiane Rordorf","raw_affiliation_strings":["Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":2.4795,"has_fulltext":false,"cited_by_count":48,"citation_normalized_percentile":{"value":0.8803681,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"42","issue":"2","first_page":"222","last_page":"228"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.6288999915122986,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.6288999915122986,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.24210000038146973,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.018799999728798866,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.9940000176429749},{"id":"https://openalex.org/keywords/atorvastatin","display_name":"atorvastatin","score":0.9470000267028809},{"id":"https://openalex.org/keywords/pravastatin","display_name":"pravastatin","score":1.0},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9900000095367432},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8050000071525574},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.902999997138977},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9890000224113464},{"id":"https://openalex.org/keywords/immunosuppressive-drugs","display_name":"immunosuppressants","score":0.9070000052452087},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.5680000185966492},{"id":"https://openalex.org/keywords/drug-co-administration","display_name":"drug co-administration","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C2777482532","wikidata":"https://www.wikidata.org/wiki/Q668093","display_name":"Atorvastatin","level":2,"score":0.9568873643875122},{"id":"https://openalex.org/C2779519902","wikidata":"https://www.wikidata.org/wiki/Q1240093","display_name":"Pravastatin","level":3,"score":0.9373782277107239},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.8739169836044312},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7812784910202026},{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.7796573638916016},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6777979135513306},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6340407133102417},{"id":"https://openalex.org/C104950815","wikidata":"https://www.wikidata.org/wiki/Q415607","display_name":"HMG-CoA reductase","level":4,"score":0.6073727607727051},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5676763653755188},{"id":"https://openalex.org/C2777320049","wikidata":"https://www.wikidata.org/wiki/Q2989497","display_name":"Hydroxymethylglutaryl-CoA reductase","level":5,"score":0.5068643689155579},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.49941468238830566},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.49264007806777954},{"id":"https://openalex.org/C134651460","wikidata":"https://www.wikidata.org/wiki/Q3100717","display_name":"Reductase","level":3,"score":0.33054274320602417},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.23248520493507385},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2316558063030243},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.1634519398212433},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.09426328539848328},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06594765186309814},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068338","descriptor_name":"Everolimus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069059","descriptor_name":"Atorvastatin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006538","descriptor_name":"Heptanoic Acids","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D006538","descriptor_name":"Heptanoic Acids","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013058","descriptor_name":"Mass Spectrometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017035","descriptor_name":"Pravastatin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D017035","descriptor_name":"Pravastatin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1177/00912700222011148","doi":"https://doi.org/10.1177/00912700222011148","is_oa":false,"landing_page_url":"https://doi.org/10.1177/00912700222011148","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:11831546","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11831546","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1970475651","https://openalex.org/W1998758469","https://openalex.org/W2005328285","https://openalex.org/W2042241032","https://openalex.org/W2044405747","https://openalex.org/W2059333451","https://openalex.org/W2093162411","https://openalex.org/W2098367156","https://openalex.org/W2102724745","https://openalex.org/W2148724358","https://openalex.org/W2160391973","https://openalex.org/W2402076506","https://openalex.org/W2403066849","https://openalex.org/W2426699212"],"related_works":["https://openalex.org/W2063521571","https://openalex.org/W2315547157","https://openalex.org/W2039688545","https://openalex.org/W2001270856","https://openalex.org/W1778499707","https://openalex.org/W2157402102","https://openalex.org/W2018126221","https://openalex.org/W2080109883","https://openalex.org/W1875385555","https://openalex.org/W2042709174"],"abstract_inverted_index":{"The":[0,73,147],"authors":[1],"assessed":[2],"the":[3,7,12,59,99,113,145,151,172,188],"mutual":[4],"influence":[5,122,187],"of":[6,75,115,127,150,178,190],"immunosuppressant":[8],"everolimus":[9,103,128,179],"(Certican)":[10],"and":[11,17,24,58,79,92,96,107,140],"HMG-CoA":[13,81,161,196],"reductase":[14,82,162,197],"inhibitors":[15,83,163,198],"atorvastatin":[16,47,95,116,124,182],"pravastatin":[18,54,97,130,138,184],"when":[19],"coadministered":[20,62],"based":[21],"on":[22,123],"pharmacokinetic":[23],"pharmacodynamic":[25],"measures.":[26],"In":[27],"this":[28],"randomized,":[29],"open-label,":[30],"three-way":[31],"crossover":[32],"study,":[33],"24":[34],"healthy":[35],"men":[36],"received":[37],"three":[38,77],"single-dose":[39],"oral":[40],"treatments:":[41],"2":[42],"mg":[43,46,53],"everolimus,":[44,191],"20":[45,52],"(n":[48,55],"=":[49,56],"12)":[50],"or":[51,183,194],"12),":[57],"respective":[60],"statin":[61,174],"with":[63,94,129,133,180],"everolimus.":[64,157],"Consecutive":[65],"treatments":[66],"were":[67,84,105,154],"separated":[68],"by":[69,90,117,156],"a":[70,134,141,202],"14-day":[71],"washout.":[72],"pharmacokinetics":[74,189],"all":[76],"drugs":[78],"total":[80,160,195],"measured.":[85],"Everolimus":[86,110],"Cmax":[87,114,139],"was":[88,131],"reduced":[89],"9%":[91],"10%":[93,135],"coadministration;":[98],"corresponding":[100],"decreases":[101],"in":[102,137,144,159,164,199],"AUC":[104],"5%":[106,142],"6%,":[108],"respectively.":[109],"coadministration":[111],"increased":[112],"11%":[118],"but":[119],"had":[120],"no":[121],"AUC.":[125,146],"Coadministration":[126],"associated":[132],"decrease":[136,143],"elimination":[148],"half-lives":[149],"two":[152],"statins":[153],"unaffected":[155],"Changes":[158],"plasma":[165,200],"exhibited":[166],"generally":[167],"similar":[168],"patterns":[169],"as":[170],"for":[171],"parent":[173],"exposures.":[175],"Single-dose":[176],"administrations":[177],"either":[181],"did":[185],"not":[186],"atorvastatin,":[192],"pravastatin,":[193],"to":[201],"clinically":[203],"relevant":[204],"extent.":[205]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}